<p>美國市場表現強勁，過去一週上漲 3.4%，過去一年上漲 35%，預計年收益增長 16%。在這樣一個繁榮的市場中，識別具有強大增長潛力的股票通常需要超越知名公司，關注那些可能不在每位投資者視野中的股票。雖然 “便士股票” 是一個較老的術語，但仍然相關，因為它們通常代表較小或較新的公司，當其財務健康良好時，可能會提供意想不到的價值和穩定性。</p>
<h3>美國十大便士股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>股價</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益與風險</strong></td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$0.3869</td>
<td>$62.22M</td>
<td>✅ 3 ⚠️ 5 查看分析 </td>
</tr>
<tr>
<td>LexinFintech Holdings (LX)</td>
<td>$2.33</td>
<td>$378.59M</td>
<td>✅ 3 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>Tuniu (TOUR)</td>
<td>$0.7401</td>
<td>$84.55M</td>
<td>✅ 2 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>Information Services Group (III)</td>
<td>$3.11</td>
<td>$194.03M</td>
<td>✅ 3 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 2 ⚠️ 5 查看分析 </td>
</tr>
<tr>
<td>Niagen Bioscience (NAGE)</td>
<td>$4.74</td>
<td>$376.36M</td>
<td>✅ 3 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>LifeVantage (LFVN)</td>
<td>$4.35</td>
<td>$52.95M</td>
<td>✅ 4 ⚠️ 3 查看分析 </td>
</tr>
<tr>
<td>Village Farms International (VFF)</td>
<td>$2.88</td>
<td>$307.33M</td>
<td>✅ 5 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>SIGA Technologies (SIGA)</td>
<td>$7.80</td>
<td>$328.13M</td>
<td>✅ 2 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Marine Petroleum Trust (MARP.S)</td>
<td>$5.00</td>
<td>$10M</td>
<td>✅ 2 ⚠️ 4 查看分析 </td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們美國便士股票篩選器的 349 只股票的完整列表。</p>
<p>讓我們從我們的專業篩選器中發現一些寶藏。</p>
<h2>Telos (TLS)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> Telos Corporation 及其子公司在美國和國際上提供網絡、雲和企業安全解決方案，市值約為 3.2526 億美元。</p>
<p><strong>運營：</strong> 該公司通過其安全網絡部門產生收入，金額為 1521 萬美元，以及其安全解決方案部門，貢獻 14960 萬美元。</p>
<p><strong>市值：</strong> 3.2526 億美元</p>
<p>Telos Corporation 市值為 3.2526 億美元，儘管顯示出顯著的收入增長，但仍處於虧損狀態，2025 年淨虧損為 3655 萬美元。儘管如此，該公司無債務，短期資產超過短期和長期負債。最近的發展包括擴展 TSA PreCheck 註冊服務，併為其 Xacta Cyber GRC 平台獲得 FedRAMP High 授權，增強其風險管理能力。Telos 的股票回購計劃反映了對其估值的信心，因為其交易價格顯著低於估計的公允價值，儘管存在內部人士拋售的擔憂。</p>
<ul>
<li>點擊這裏通過我們的詳細財務健康報告發現 Telos 的細微差別。</li>
<li>通過我們的詳細增長報告評估 Telos 的未來收益預期。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/cf8637cb-0cc5-4c04-9e00-f13f14bb852e/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/cf8637cb-0cc5-4c04-9e00-f13f14bb852e/chart/debt-equity-history-analysis"/></p>
<p>截至 2026 年 4 月 TLS 債務與股本歷史及分析</p>
<h2>InflaRx (IFRX)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> InflaRx N.V.是一家臨牀階段的生物製藥公司，專注於在德國和美國發現和開發 C5a 抑制劑技術，市值為 8241 萬美元。</p>
<p><strong>運營：</strong> InflaRx 主要通過其製藥部門產生收入，金額為 3 萬歐元。</p>
<p><strong>市值：</strong> 8241 萬美元</p>
<p>InflaRx 市值為 8241 萬美元，是一家尚未產生收入的生物製藥公司，專注於 C5a 抑制劑技術。該公司最近的體外研究結果突顯了 izicopan 在藥物相互作用方面的低風險，增強了其藥理特徵。然而，InflaRx 在財務穩定性方面面臨挑戰，審計師對其持續經營能力表示懷疑。儘管針對膿皰性壞死性筋膜炎的 vilobelimab 的第三階段試驗顯示出一些有希望的結果，但由於無效的擔憂而提前終止。該公司無債務，並且在當前條件下有超過一年的現金流。</p>
<ul>
<li>點擊這裏通過我們的資產負債表健康報告深入瞭解 InflaRx 的表現。</li>
<li>通過我們的公司收益預期報告獲取對 InflaRx 前景和預期表現的見解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/15298cd0-d408-4bf2-904a-9edef263d494/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/15298cd0-d408-4bf2-904a-9edef263d494/chart/debt-equity-history-analysis"/></p>
<p>截至 2026 年 4 月 IFRX 債務與股本歷史及分析</p>
<h2>Endava (DAVA)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Endava plc 及其子公司在北美、歐洲、英國及國際上提供技術服務，市值為 2.3462 億美元。</p>
<p><strong>運營：</strong> 該公司通過其計算機服務部門產生 7439 萬英鎊的收入。</p>
<p><strong>市值：</strong> 2.3462 億美元</p>
<p>Endava 市值為 2.3462 億美元，面臨挑戰，因為它仍處於虧損狀態，過去五年損失不斷增加。儘管與同行相比交易價格合理，並保持令人滿意的債務水平，但預計其收益將以每年 98.6% 的速度顯著增長。最近的指導顯示 2026 財年的收入略有下降，而戰略合作伙伴關係旨在通過 Dava.Flow™增強 AI 原生交付能力。該公司還完成了重大股票回購，減少了 13.59% 的流通股，這可能在持續的運營改善中對股東價值產生積極影響。</p>
<ul>
<li>點擊這裏深入瞭解 Endava 的具體情況，通過我們的資產負債表健康報告。</li>
<li>通過查看我們的增長報告獲取對 Endava 未來方向的見解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a31bb721-eaae-48a2-abe6-f764585ca399/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a31bb721-eaae-48a2-abe6-f764585ca399/chart/debt-equity-history-analysis"/></p>
<p>截至 2026 年 4 月 DAVA 債務與股本歷史及分析</p>
<h2>關鍵要點</h2>
<ul>
<li>點擊這裏開始探索其餘的 346 只美國便士股票。</li>
<li>尋找其他投資？尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
<p><em>這篇文章來自 Simply Wall St，內容具有一般性。<strong>我們基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
<h3>估值是複雜的，但我們在這裏為您簡化。</h3>
<p>通過我們的詳細分析，發現 Endava 是否可能被低估或高估，分析內容包括 <strong>公允價值估計、潛在風險、股息、內部交易和財務狀況。</strong></p>
<p>獲取免費分析</p>

IFRX

DAVA

樂信集團

MAPS

<p>美國市場在過去一週上漲了 3.4%，在過去一年中上漲了 35%，預計年收益增長將達到 16%。這種環境鼓勵投資者探索低價股，這些股票可能提供意想不到的價值。值得注意的低價股包括 WM Tech、樂信集團和 Telos Corporation，儘管這些公司尚未盈利，但由於其無債務狀態和收入增長，顯示出潛力。InflaRx 是一家臨牀階段的生物製藥公司，面臨財務穩定性挑戰，但仍保持無債務。Endava 雖然未盈利，但預計將實現顯著的收益增長，並已進行股票回購以提升股東價值</p>

<p>The United States market has shown robust performance, rising 3.4% over the last week and 35% over the past year, with earnings projected to grow by 16% annually. In such a thriving market, identifying stocks with strong potential for growth often involves looking beyond well-known names to those that might not be on every investor's radar. Penny stocks, though an older term, remain relevant as they often represent smaller or newer companies that could offer surprising value and stability when backed by solid financial health.</p>
<div class="lb-trans"><p>美國市場表現強勁，過去一週上漲 3.4%，過去一年上漲 35%，預計年收益增長 16%。在這樣一個繁榮的市場中，識別具有強大增長潛力的股票通常需要超越知名公司，關注那些可能不在每位投資者視野中的股票。雖然 “便士股票” 是一個較老的術語，但仍然相關，因為它們通常代表較小或較新的公司，當其財務健康良好時，可能會提供意想不到的價值和穩定性。</p>
</div><h3>Top 10 Penny Stocks In The United States</h3>
<div class="lb-trans"><h3>美國十大便士股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Share Price</strong></td>
<td><strong>Market Cap</strong></td>
<td><strong>Rewards &amp; Risks</strong></td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$0.3869</td>
<td>$62.22M</td>
<td>✅ 3 ⚠️ 5 View Analysis &gt;</td>
</tr>
<tr>
<td>LexinFintech Holdings (LX)</td>
<td>$2.33</td>
<td>$378.59M</td>
<td>✅ 3 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Tuniu (TOUR)</td>
<td>$0.7401</td>
<td>$84.55M</td>
<td>✅ 2 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Information Services Group (III)</td>
<td>$3.11</td>
<td>$194.03M</td>
<td>✅ 3 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 2 ⚠️ 5 View Analysis &gt;</td>
</tr>
<tr>
<td>Niagen Bioscience (NAGE)</td>
<td>$4.74</td>
<td>$376.36M</td>
<td>✅ 3 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>LifeVantage (LFVN)</td>
<td>$4.35</td>
<td>$52.95M</td>
<td>✅ 4 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>Village Farms International (VFF)</td>
<td>$2.88</td>
<td>$307.33M</td>
<td>✅ 5 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>SIGA Technologies (SIGA)</td>
<td>$7.80</td>
<td>$328.13M</td>
<td>✅ 2 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Marine Petroleum Trust (MARP.S)</td>
<td>$5.00</td>
<td>$10M</td>
<td>✅ 2 ⚠️ 4 View Analysis &gt;</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>股價</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益與風險</strong></td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$0.3869</td>
<td>$62.22M</td>
<td>✅ 3 ⚠️ 5 查看分析 </td>
</tr>
<tr>
<td>LexinFintech Holdings (LX)</td>
<td>$2.33</td>
<td>$378.59M</td>
<td>✅ 3 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>Tuniu (TOUR)</td>
<td>$0.7401</td>
<td>$84.55M</td>
<td>✅ 2 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>Information Services Group (III)</td>
<td>$3.11</td>
<td>$194.03M</td>
<td>✅ 3 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 2 ⚠️ 5 查看分析 </td>
</tr>
<tr>
<td>Niagen Bioscience (NAGE)</td>
<td>$4.74</td>
<td>$376.36M</td>
<td>✅ 3 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>LifeVantage (LFVN)</td>
<td>$4.35</td>
<td>$52.95M</td>
<td>✅ 4 ⚠️ 3 查看分析 </td>
</tr>
<tr>
<td>Village Farms International (VFF)</td>
<td>$2.88</td>
<td>$307.33M</td>
<td>✅ 5 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>SIGA Technologies (SIGA)</td>
<td>$7.80</td>
<td>$328.13M</td>
<td>✅ 2 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Marine Petroleum Trust (MARP.S)</td>
<td>$5.00</td>
<td>$10M</td>
<td>✅ 2 ⚠️ 4 查看分析 </td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 349 stocks from our US Penny Stocks screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們美國便士股票篩選器的 349 只股票的完整列表。</p>
</div><p>Let's uncover some gems from our specialized screener.</p>
<div class="lb-trans"><p>讓我們從我們的專業篩選器中發現一些寶藏。</p>
</div><h2>Telos (TLS)</h2>
<div class="lb-trans"><h2>Telos (TLS)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Telos Corporation, along with its subsidiaries, offers cyber, cloud, and enterprise security solutions both in the United States and internationally, with a market cap of approximately $325.26 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Telos Corporation 及其子公司在美國和國際上提供網絡、雲和企業安全解決方案，市值約為 3.2526 億美元。</p>
</div><p><strong>Operations:</strong> The company generates revenue through its Secure Networks segment, which accounts for $15.21 million, and its Security Solutions segment, contributing $149.6 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司通過其安全網絡部門產生收入，金額為 1521 萬美元，以及其安全解決方案部門，貢獻 14960 萬美元。</p>
</div><p><strong>Market Cap:</strong> $325.26M</p>
<div class="lb-trans"><p><strong>市值：</strong> 3.2526 億美元</p>
</div><p>Telos Corporation, with a market cap of US$325.26 million, has shown significant revenue growth but remains unprofitable, posting a net loss of US$36.55 million for 2025. Despite this, the company is debt-free and its short-term assets exceed both short and long-term liabilities. Recent developments include the expansion of TSA PreCheck enrollment services and achieving FedRAMP High authorization for its Xacta Cyber GRC platform, enhancing its risk management capabilities. Telos's share buyback program reflects confidence in its valuation as it trades significantly below estimated fair value despite insider selling concerns.</p>
<div class="lb-trans"><p>Telos Corporation 市值為 3.2526 億美元，儘管顯示出顯著的收入增長，但仍處於虧損狀態，2025 年淨虧損為 3655 萬美元。儘管如此，該公司無債務，短期資產超過短期和長期負債。最近的發展包括擴展 TSA PreCheck 註冊服務，併為其 Xacta Cyber GRC 平台獲得 FedRAMP High 授權，增強其風險管理能力。Telos 的股票回購計劃反映了對其估值的信心，因為其交易價格顯著低於估計的公允價值，儘管存在內部人士拋售的擔憂。</p>
</div><ul>
<li>Click here to discover the nuances of Telos with our detailed analytical financial health report.</li>
<li>Assess Telos' future earnings estimates with our detailed growth reports.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏通過我們的詳細財務健康報告發現 Telos 的細微差別。</li>
<li>通過我們的詳細增長報告評估 Telos 的未來收益預期。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/cf8637cb-0cc5-4c04-9e00-f13f14bb852e/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/cf8637cb-0cc5-4c04-9e00-f13f14bb852e/chart/debt-equity-history-analysis"/></p>
<p>TLS Debt to Equity History and Analysis as at Apr 2026</p>
<div class="lb-trans"><p>截至 2026 年 4 月 TLS 債務與股本歷史及分析</p>
</div><h2>InflaRx (IFRX)</h2>
<div class="lb-trans"><h2>InflaRx (IFRX)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> InflaRx N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing C5a inhibitor technology in Germany and the United States, with a market cap of $82.41 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> InflaRx N.V.是一家臨牀階段的生物製藥公司，專注於在德國和美國發現和開發 C5a 抑制劑技術，市值為 8241 萬美元。</p>
</div><p><strong>Operations:</strong> InflaRx generates its revenue primarily from its Pharmaceuticals segment, which amounts to €0.03 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> InflaRx 主要通過其製藥部門產生收入，金額為 3 萬歐元。</p>
</div><p><strong>Market Cap:</strong> $82.41M</p>
<div class="lb-trans"><p><strong>市值：</strong> 8241 萬美元</p>
</div><p>InflaRx, with a market cap of $82.41 million, is a pre-revenue biopharmaceutical company focusing on C5a inhibitor technology. The company's recent in vitro findings highlight izicopan's low risk for drug-drug interactions, enhancing its pharmacological profile. However, InflaRx faces challenges with its financial stability as auditors have expressed doubts about its ability to continue as a going concern. While the Phase 3 trial for vilobelimab in pyoderma gangrenosum showed some promising results, it was terminated early due to futility concerns. The company remains debt-free and has sufficient cash runway for over a year if current conditions persist.</p>
<div class="lb-trans"><p>InflaRx 市值為 8241 萬美元，是一家尚未產生收入的生物製藥公司，專注於 C5a 抑制劑技術。該公司最近的體外研究結果突顯了 izicopan 在藥物相互作用方面的低風險，增強了其藥理特徵。然而，InflaRx 在財務穩定性方面面臨挑戰，審計師對其持續經營能力表示懷疑。儘管針對膿皰性壞死性筋膜炎的 vilobelimab 的第三階段試驗顯示出一些有希望的結果，但由於無效的擔憂而提前終止。該公司無債務，並且在當前條件下有超過一年的現金流。</p>
</div><ul>
<li>Get an in-depth perspective on InflaRx's performance by reading our balance sheet health report here.</li>
<li>Gain insights into InflaRx's outlook and expected performance with our report on the company's earnings estimates.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏通過我們的資產負債表健康報告深入瞭解 InflaRx 的表現。</li>
<li>通過我們的公司收益預期報告獲取對 InflaRx 前景和預期表現的見解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/15298cd0-d408-4bf2-904a-9edef263d494/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/15298cd0-d408-4bf2-904a-9edef263d494/chart/debt-equity-history-analysis"/></p>
<p>IFRX Debt to Equity History and Analysis as at Apr 2026</p>
<div class="lb-trans"><p>截至 2026 年 4 月 IFRX 債務與股本歷史及分析</p>
</div><h2>Endava (DAVA)</h2>
<div class="lb-trans"><h2>Endava (DAVA)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Endava plc, along with its subsidiaries, offers technology services across North America, Europe, the United Kingdom, and internationally, with a market cap of $234.62 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Endava plc 及其子公司在北美、歐洲、英國及國際上提供技術服務，市值為 2.3462 億美元。</p>
</div><p><strong>Operations:</strong> The company generates £743.90 million in revenue from its computer services segment.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司通過其計算機服務部門產生 7439 萬英鎊的收入。</p>
</div><p><strong>Market Cap:</strong> $234.62M</p>
<div class="lb-trans"><p><strong>市值：</strong> 2.3462 億美元</p>
</div><p>Endava, with a market cap of US$234.62 million, is navigating challenges as it remains unprofitable with increasing losses over the past five years. Despite trading at a good value compared to peers and maintaining satisfactory debt levels, its earnings are forecast to grow significantly at 98.6% per year. Recent guidance indicates a slight revenue decline for fiscal 2026, while strategic partnerships aim to enhance AI-native delivery capabilities through Dava.Flow™?. The company has also completed significant share buybacks, reducing outstanding shares by 13.59%, which may influence shareholder value positively amidst ongoing operational improvements.</p>
<div class="lb-trans"><p>Endava 市值為 2.3462 億美元，面臨挑戰，因為它仍處於虧損狀態，過去五年損失不斷增加。儘管與同行相比交易價格合理，並保持令人滿意的債務水平，但預計其收益將以每年 98.6% 的速度顯著增長。最近的指導顯示 2026 財年的收入略有下降，而戰略合作伙伴關係旨在通過 Dava.Flow™增強 AI 原生交付能力。該公司還完成了重大股票回購，減少了 13.59% 的流通股，這可能在持續的運營改善中對股東價值產生積極影響。</p>
</div><ul>
<li>Dive into the specifics of Endava here with our thorough balance sheet health report.</li>
<li>Gain insights into Endava's future direction by reviewing our growth report.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏深入瞭解 Endava 的具體情況，通過我們的資產負債表健康報告。</li>
<li>通過查看我們的增長報告獲取對 Endava 未來方向的見解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a31bb721-eaae-48a2-abe6-f764585ca399/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/a31bb721-eaae-48a2-abe6-f764585ca399/chart/debt-equity-history-analysis"/></p>
<p>DAVA Debt to Equity History and Analysis as at Apr 2026</p>
<div class="lb-trans"><p>截至 2026 年 4 月 DAVA 債務與股本歷史及分析</p>
</div><h2>Key Takeaways</h2>
<div class="lb-trans"><h2>關鍵要點</h2>
</div><ul>
<li>Click through to start exploring the rest of the 346 US Penny Stocks now.</li>
<li>Seeking Other Investments? Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏開始探索其餘的 346 只美國便士股票。</li>
<li>尋找其他投資？尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇文章來自 Simply Wall St，內容具有一般性。<strong>我們基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div><h3>Valuation is complex, but we're here to simplify it.</h3>
<div class="lb-trans"><h3>估值是複雜的，但我們在這裏為您簡化。</h3>
</div><p>Discover if Endava might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p>
<div class="lb-trans"><p>通過我們的詳細分析，發現 Endava 是否可能被低估或高估，分析內容包括 <strong>公允價值估計、潛在風險、股息、內部交易和財務狀況。</strong></p>
</div><p>Access Free Analysis</p>
<div class="lb-trans"><p>獲取免費分析</p>
</div>

2026 年 4 月值得關注的具有潛在增長機會的便士股票